Table 1. Baseline seropositive rates of HBsAg and anti-HBc and seroprotective rate of anti-HBs by HB vaccination history.
| Vaccination history | N (%) | HBsAg | Anti-HBc alone | Anti-HBc+anti-HBs both positive | Anti-HBs alone | All negative | Anti-HBs GMC1(IU/L) | Anti-HBs GMC2(IU/L) |
|---|---|---|---|---|---|---|---|---|
| Confirmed | 226 (11.1) | 12 (5.3, 2.8–9.1) | 5 (2.2, 0.7–5.1) | 73 (32.3, 26.3–38.8) | 85 (37.6, 31.3–44.3) | 51 (22.6, 17.3–28.6) | 41.3 (27.7–61.8) | 49.3 (32.9–74.0) |
| 1 or 2 doses | 11 (0.5) | 0 (0, 0–28.5) | 0 (0, 0–28.5) | 8 (72.7, 39.0–94.0) | 2 (18.2, 2.3–51.8) | 1 (9.1, 0.2–41.3) | 137.3 (30.7–614.2) | 137.3 (30.7–614.2) |
| 3 doses | 215 (10.5) | 12 (5.6, 2.9–9.5) | 5 (2.3, 0.8–5.3) | 65 (30.2, 24.2–36.8) | 83 (38.6, 32.1–45.5) | 50 (23.2, 17.8–29.5) | 38.9 (25.7–58.9) | 46.7 (30.6–71.1) |
| Within 24 hr after birth | 65 (3.2) | 1 (1.5, 0.04–8.3) | 1 (1.5, 0.04–8.3) | 15 (23.1, 13.5–35.2) | 30 (46.2, 33.7–59.0) | 18 (27.7, 17.3–40.2) | 27.7 (12.9–59.9) | 29.7 (13.7–64.1) |
| Beyond 24 hr after birth | 150 (7.3) | 11 (7.3, 3.7–12.7) | 4 (2.7, 0.7–6.7) | 50 (33.3, 25.9–41.5) | 53 (35.3, 27.7–43.5) | 32 (21.3, 15.1–28.8) | 42.8 (26.0–70.5) | 52.5 (31.6–87.2) |
| Unknown | 1648 (80.8) | 225 (13.6, 12.0–15.4) | 29 (1.8, 1.2–2.5) | 486 (29.5, 27.3–31.8) | 417 (25.3, 23.2–27.5) | 491 (29.8, 27.6–32.1) | 14.2 (12.2–16.6) | 22.2 (18.8–26.1) |
| None | 166 (8.1) | 21 (12.6, 8.0–18.7) | 8 (4.8, 2.1–9.3) | 56 (33.7, 26.6–41.5) | 23 (13.8, 9.0–20.1) | 58 (34.9, 27.7–42.7) | 11.6 (6.9–19.4) | 18.3 (10.6–31.6) |
| Total | 2040 (100.0) | 258 (12.6, 11.2–14.2) | 42 (2.1, 1.5–2.8) | 615 (30.1, 28.2–32.2) | 525 (25.7, 23.8–27.7) | 600 (29.4, 27.4–31.4) | 15.7 (13.7–18.1) | 24.0 (20.7–27.8) |
Data are presented as participant number or value (proportion of participants and/or 95%CI). N, Number of participants with different HB vaccination history; %, proportion of participants with different HB vaccination history among total participants; 95%, 95% confidence interval; GMC1, calculated on all the participants with specific vaccination history; GMC2, calculated on the participants other than HBsAg positive. For HBsAg seropositive rate: P = 0.0019 among the participants with confirmed, unknown or none vaccination history; P = 0.0004, 0.0097, 0.7192 for confirmed vs. unknown, confirmed vs. none, unknown vs. none, respectively; within 24 h vs. beyond 24 h: P = 0.1123. For anti-HBs alone seroprotective rate: P < 0.0001 among the participants with confirmed, unknown or none vaccination history; P < 0.0001, < 0.0001, = 0.0010 for confirmed vs. unknown, confirmed vs. none, unknown vs. none, respectively; within 24 h vs. beyond 24 h: P = 0.1345. For GMC1: P < 0.0001 among the participants with confirmed, unknown or none vaccination history; P < 0.0001, = 0.0002, = 0.5083 for confirmed vs. unknown, confirmed vs. none, unknown vs. none, respectively; within 24 h vs. beyond 24 h: P = 0.3482. For GMC2: P = 0.0014 among the participants with confirmed, unknown or none vaccination history; P = 0.0006, 0.0035, 0.4855 for confirmed vs. unknown, confirmed vs. none, unknown vs. none, respectively; within 24 h vs. beyond 24 h: P = 0.2172. For multiple comparison, Bonferroni adjustment was used with α’ = α/month = 0.05/3 = 0.0167.